ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 088,24
0,89%
Dow Jones
38 239,66
0,40%
DAX
18 161,01
1,32%
Brent Oil
88,165
0,00%
Bitcoin
63 721,28
0,49%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Galmed Pharmaceuticals Ltd (GLMD)

  7. Galmed Pharmaceuticals Ltd (GLMD) Actualités

GLMD Galmed Pharmaceuticals Ltd

0,3916
-0,0009 (-0,23%)
27 Avr 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Galmed Pharmaceuticals Ltd GLMD NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,0009 -0,23% 0,3916 06:00:04
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
0,3949 0,367 0,3949 0,3916 0,3925
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
04/4/202423:06PRNUSGalmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F..
15/3/202414:00PRNUSGalmed Announces Grant of New Patent for the Combination of..
14/2/202420:14EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
12/2/202422:15EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
30/11/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
22/11/202322:48EDGAR2Form POS AM - Post-Effective amendments for registration..
20/11/202322:37EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/11/202322:32PRNUSGalmed Announces a delay in the initiation of its Primary..
01/11/202321:15EDGAR2Form POS AM - Post-Effective amendments for registration..
26/9/202314:51EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
26/9/202314:30PRNUSGalmed Announces Allowance of New Patent for Aramchol for..
22/9/202322:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
22/9/202322:05PRNUSGalmed Pharmaceuticals Announces Receipt of Nasdaq Minimum..
21/9/202313:30EDGAR2Form 6-K/A - Report of foreign issuer [Rules 13a-16 and..
20/9/202322:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13/9/202322:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/8/202322:43EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/8/202322:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
02/8/202322:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/7/202316:12EDGAR2Form SC 13G - Statement of acquisition of beneficial..
18/7/202315:25EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18/7/202315:23EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
14/7/202315:44EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/7/202315:30PRNUSGalmed Pharmaceuticals Announces Pricing of $7 Million..
13/7/202323:08EDGAR2Form F-1/A - Registration statement for certain foreign..
12/7/202323:29EDGAR2Form F-1/A - Registration statement for certain foreign..
10/7/202314:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/7/202314:00PRNUSGalmed to employ OnKai's disruptive Artificial Intelligence..
28/6/202314:40EDGAR2Form FWP - Filing under Securities Act Rules 163/433 of free..
28/6/202314:37EDGAR2Form F-1/A - Registration statement for certain foreign..
01/6/202314:00PRNUSGalmed Pharmaceuticals Reports First Quarter 2023 Financial..
09/5/202313:00PRNUSGalmed Announces Initiation of a Clinical Development..

Dernières Valeurs Consultées

NASDAQ
GLMD
Galmed Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés